Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPELINE-RSV adaptive platform trial
2025-522194-11-00Phase 3Authorised
- Sponsor
- Penta Foundation
- Start
- Jul 2026
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, open-label trial of RSVpreF vaccine and nirsevimab in respiratory syncytial virus disease (RSV) (2 arms), sponsored by Penta Foundation. Planned start Jul 2026; status: authorised.
02
Drugs
RSVpreF vaccinenirsevimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2025-522194-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522194-11-00.